BMJ Open (Apr 2022)

Impact of quality improvement initiatives to improve CKD referral patterns: a systematic review protocol

  • Paul E Ronksley,
  • Alexander Singer,
  • Andrew Wong,
  • Soroush Shojai,
  • Ikechi Okpechi,
  • Kailash Jindal,
  • Branko Braam,
  • Scott Klarenbach,
  • Feng Ye,
  • Kenneth Scott Brimble,
  • Allan K Grill,
  • Ayub Akbari,
  • Nikhil Shah,
  • Laura N Hamonic,
  • David Collister,
  • Anukul Ghimire,
  • Naima Sultana,
  • Mark Courtney,
  • Sabin Shurraw,
  • Sophia Chou,
  • Vinay Deved,
  • A K Bello

DOI
https://doi.org/10.1136/bmjopen-2021-055456
Journal volume & issue
Vol. 12, no. 4

Abstract

Read online

Introduction Chronic kidney disease (CKD) is a global-health problem. A significant proportion of referrals to nephrologists for CKD management are early and guideline-discordant, which may lead to an excess number of referrals and increased wait-times. Various initiatives have been tested to increase the proportion of guideline-concordant referrals and decrease wait times. This paper describes the protocol for a systematic review to study the impacts of quality improvement initiatives aimed at decreasing the number of non-guideline concordant referrals, increasing the number of guideline-concordant referrals and decreasing wait times for patients to access a nephrologist.Methods and analysis We developed this protocol by using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols (2015). We will search the following empirical electronic databases: MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, PsycINFO and grey literature for studies designed to improve guideline-concordant referrals or to reduce unnecessary referrals of patients with CKD from primary care to nephrology. Our search will include all studies published from database inception to April 2021 with no language restrictions. The studies will be limited to referrals for adult patients to nephrologists. Referrals of patients with CKD from non-nephrology specialists (eg, general internal medicine) will be excluded.Ethics and dissemination Ethics approval will not be required, as we will analyse data from studies that have already been published and are publicly accessible. We will share our findings using traditional approaches, including scientific presentations, open access peer-reviewed platforms, and appropriate government and public health agencies.PROSPERO registration number CRD42021247756.